hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company also provides clinical research services, including early-phase trials and human pharmacological studies. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.…
hVIVO (LSE:HVO) Completes Its Board Refresh With a New Finance Chief This Month for Shareholders
hVIVO (LON: HVO) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 376 employees.
The shares were at 4.550 GBp on 20 November 2026, down 21.6% over 52 weeks. Its 52-week range is 4.305 GBp to 11.00 GBp: the price is 58.6% below the high and 5.7% above the low.
Its market capitalisation is 31.32M GBP.
hVIVO reports return on equity of -15.7%, an operating margin of -26.2% and revenue down 29.7% year over year.
Its debt exceeds its cash by 936.00K GBP, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 7 analysts cover the stock; their mean price target of 15.50 GBp is 240.7% above the current price.
No upcoming events tracked.